Molecular pathology and novel clinical therapy for uterine leiomyosarcoma

Takuma Hayashi, Miki Kawano, Tomoyuki Ichimura, Koichi Ida, Hirofumi Ando, Dorit Zharhary, Yae Kanai, Hiroyuki Aburatani, Susumu Tonegawa, Tanri Shiozawa, Nobuo Yaegashi, Ikuo Konishi

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Patients with uterine leiomyosarcoma (LMS) typically present with vaginal bleeding, pain, and a pelvic mass, with atypical presentations of hypercalcemia and eosinophilia also being reported. Radiographic evaluation with combined positron-emission tomography/computed tomography may assist in diagnosis and surveillance in women with uterine LMS; these are commonly used with stage and tumour grade as prognostic indicators and a recently developed risk-assessment index to predict disease-specific survival. Recent studies have shown that the addition of adjuvant therapy after surgical management does not seem to improve survival, and ovarian preservation does not appear to negatively impact outcome. Experimentally, it is noteworthy that proteasome subunit beta 9 (PSMB9)/1i-deficient mice exhibit spontaneous development of uterine LMS, with a disease prevalence of ~37% by 12 months of age. Furthermore, a recent report showed the loss of ability to induce PSMB9/1i expression, that is up-regulated by interferon-(IFN), in human uterine LMS tissues. Here, we reviewed human uterine LMS for genetic mutations in the IFN signal cascade, and found serious mutations in three genes, Janus activated kinase 1 (JAK1), signal transducer and activator of transcription 1 (STAT1) and PSMB9/1i promoter regions. Moreover, molecular experiments demonstrated differential expression of cyclin E and P27/KIP1, that regulate cell-cycle G1 arrest via PSMB9/1i expression. The discovery of this mutational activation of a key cell-signalling pathway may provide new targets for diagnostic approaches and therapeutic intervention.

Original languageEnglish
Pages (from-to)4997-5007
Number of pages11
JournalAnticancer Research
Volume36
Issue number10
DOIs
Publication statusPublished - 2016 Oct 1

Fingerprint

Leiomyosarcoma
Molecular Pathology
Proteasome Endopeptidase Complex
Janus Kinase 1
STAT1 Transcription Factor
G1 Phase Cell Cycle Checkpoints
Therapeutics
Cyclin E
Mutation
Pelvic Pain
Survival
Uterine Hemorrhage
Hypercalcemia
Eosinophilia
Genetic Promoter Regions
Interferons
Genes
Neoplasms

Keywords

  • Cyclin E
  • IFN
  • PSMB9/1i
  • Review
  • Uterine leiomyosarcoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hayashi, T., Kawano, M., Ichimura, T., Ida, K., Ando, H., Zharhary, D., ... Konishi, I. (2016). Molecular pathology and novel clinical therapy for uterine leiomyosarcoma. Anticancer Research, 36(10), 4997-5007. https://doi.org/10.21873/anticanres.11068

Molecular pathology and novel clinical therapy for uterine leiomyosarcoma. / Hayashi, Takuma; Kawano, Miki; Ichimura, Tomoyuki; Ida, Koichi; Ando, Hirofumi; Zharhary, Dorit; Kanai, Yae; Aburatani, Hiroyuki; Tonegawa, Susumu; Shiozawa, Tanri; Yaegashi, Nobuo; Konishi, Ikuo.

In: Anticancer Research, Vol. 36, No. 10, 01.10.2016, p. 4997-5007.

Research output: Contribution to journalReview article

Hayashi, T, Kawano, M, Ichimura, T, Ida, K, Ando, H, Zharhary, D, Kanai, Y, Aburatani, H, Tonegawa, S, Shiozawa, T, Yaegashi, N & Konishi, I 2016, 'Molecular pathology and novel clinical therapy for uterine leiomyosarcoma', Anticancer Research, vol. 36, no. 10, pp. 4997-5007. https://doi.org/10.21873/anticanres.11068
Hayashi T, Kawano M, Ichimura T, Ida K, Ando H, Zharhary D et al. Molecular pathology and novel clinical therapy for uterine leiomyosarcoma. Anticancer Research. 2016 Oct 1;36(10):4997-5007. https://doi.org/10.21873/anticanres.11068
Hayashi, Takuma ; Kawano, Miki ; Ichimura, Tomoyuki ; Ida, Koichi ; Ando, Hirofumi ; Zharhary, Dorit ; Kanai, Yae ; Aburatani, Hiroyuki ; Tonegawa, Susumu ; Shiozawa, Tanri ; Yaegashi, Nobuo ; Konishi, Ikuo. / Molecular pathology and novel clinical therapy for uterine leiomyosarcoma. In: Anticancer Research. 2016 ; Vol. 36, No. 10. pp. 4997-5007.
@article{ea8f79bcd866490cad8bf1ba6b12e69c,
title = "Molecular pathology and novel clinical therapy for uterine leiomyosarcoma",
abstract = "Patients with uterine leiomyosarcoma (LMS) typically present with vaginal bleeding, pain, and a pelvic mass, with atypical presentations of hypercalcemia and eosinophilia also being reported. Radiographic evaluation with combined positron-emission tomography/computed tomography may assist in diagnosis and surveillance in women with uterine LMS; these are commonly used with stage and tumour grade as prognostic indicators and a recently developed risk-assessment index to predict disease-specific survival. Recent studies have shown that the addition of adjuvant therapy after surgical management does not seem to improve survival, and ovarian preservation does not appear to negatively impact outcome. Experimentally, it is noteworthy that proteasome subunit beta 9 (PSMB9)/1i-deficient mice exhibit spontaneous development of uterine LMS, with a disease prevalence of ~37{\%} by 12 months of age. Furthermore, a recent report showed the loss of ability to induce PSMB9/1i expression, that is up-regulated by interferon-(IFN), in human uterine LMS tissues. Here, we reviewed human uterine LMS for genetic mutations in the IFN signal cascade, and found serious mutations in three genes, Janus activated kinase 1 (JAK1), signal transducer and activator of transcription 1 (STAT1) and PSMB9/1i promoter regions. Moreover, molecular experiments demonstrated differential expression of cyclin E and P27/KIP1, that regulate cell-cycle G1 arrest via PSMB9/1i expression. The discovery of this mutational activation of a key cell-signalling pathway may provide new targets for diagnostic approaches and therapeutic intervention.",
keywords = "Cyclin E, IFN, PSMB9/1i, Review, Uterine leiomyosarcoma",
author = "Takuma Hayashi and Miki Kawano and Tomoyuki Ichimura and Koichi Ida and Hirofumi Ando and Dorit Zharhary and Yae Kanai and Hiroyuki Aburatani and Susumu Tonegawa and Tanri Shiozawa and Nobuo Yaegashi and Ikuo Konishi",
year = "2016",
month = "10",
day = "1",
doi = "10.21873/anticanres.11068",
language = "English",
volume = "36",
pages = "4997--5007",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "10",

}

TY - JOUR

T1 - Molecular pathology and novel clinical therapy for uterine leiomyosarcoma

AU - Hayashi, Takuma

AU - Kawano, Miki

AU - Ichimura, Tomoyuki

AU - Ida, Koichi

AU - Ando, Hirofumi

AU - Zharhary, Dorit

AU - Kanai, Yae

AU - Aburatani, Hiroyuki

AU - Tonegawa, Susumu

AU - Shiozawa, Tanri

AU - Yaegashi, Nobuo

AU - Konishi, Ikuo

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Patients with uterine leiomyosarcoma (LMS) typically present with vaginal bleeding, pain, and a pelvic mass, with atypical presentations of hypercalcemia and eosinophilia also being reported. Radiographic evaluation with combined positron-emission tomography/computed tomography may assist in diagnosis and surveillance in women with uterine LMS; these are commonly used with stage and tumour grade as prognostic indicators and a recently developed risk-assessment index to predict disease-specific survival. Recent studies have shown that the addition of adjuvant therapy after surgical management does not seem to improve survival, and ovarian preservation does not appear to negatively impact outcome. Experimentally, it is noteworthy that proteasome subunit beta 9 (PSMB9)/1i-deficient mice exhibit spontaneous development of uterine LMS, with a disease prevalence of ~37% by 12 months of age. Furthermore, a recent report showed the loss of ability to induce PSMB9/1i expression, that is up-regulated by interferon-(IFN), in human uterine LMS tissues. Here, we reviewed human uterine LMS for genetic mutations in the IFN signal cascade, and found serious mutations in three genes, Janus activated kinase 1 (JAK1), signal transducer and activator of transcription 1 (STAT1) and PSMB9/1i promoter regions. Moreover, molecular experiments demonstrated differential expression of cyclin E and P27/KIP1, that regulate cell-cycle G1 arrest via PSMB9/1i expression. The discovery of this mutational activation of a key cell-signalling pathway may provide new targets for diagnostic approaches and therapeutic intervention.

AB - Patients with uterine leiomyosarcoma (LMS) typically present with vaginal bleeding, pain, and a pelvic mass, with atypical presentations of hypercalcemia and eosinophilia also being reported. Radiographic evaluation with combined positron-emission tomography/computed tomography may assist in diagnosis and surveillance in women with uterine LMS; these are commonly used with stage and tumour grade as prognostic indicators and a recently developed risk-assessment index to predict disease-specific survival. Recent studies have shown that the addition of adjuvant therapy after surgical management does not seem to improve survival, and ovarian preservation does not appear to negatively impact outcome. Experimentally, it is noteworthy that proteasome subunit beta 9 (PSMB9)/1i-deficient mice exhibit spontaneous development of uterine LMS, with a disease prevalence of ~37% by 12 months of age. Furthermore, a recent report showed the loss of ability to induce PSMB9/1i expression, that is up-regulated by interferon-(IFN), in human uterine LMS tissues. Here, we reviewed human uterine LMS for genetic mutations in the IFN signal cascade, and found serious mutations in three genes, Janus activated kinase 1 (JAK1), signal transducer and activator of transcription 1 (STAT1) and PSMB9/1i promoter regions. Moreover, molecular experiments demonstrated differential expression of cyclin E and P27/KIP1, that regulate cell-cycle G1 arrest via PSMB9/1i expression. The discovery of this mutational activation of a key cell-signalling pathway may provide new targets for diagnostic approaches and therapeutic intervention.

KW - Cyclin E

KW - IFN

KW - PSMB9/1i

KW - Review

KW - Uterine leiomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=84991826608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991826608&partnerID=8YFLogxK

U2 - 10.21873/anticanres.11068

DO - 10.21873/anticanres.11068

M3 - Review article

VL - 36

SP - 4997

EP - 5007

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -